Cyber Monday Deal: Up to 60% off InvestingProCLAIM SALE

Teva Pharmaceutical Industries Ltd (TEVA)

Tel Aviv
Currency in ILS
6,330
+130(+2.10%)
Delayed Data

TEVA Income Statement

Advanced Income Statement
Period Ending:
2014
31/12
2015
31/12
2016
31/12
2017
31/12
2018
31/12
2019
31/12
2020
31/12
2021
31/12
2022
31/12
2023
31/12
Total Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa16,88716,65915,87814,92515,846
Total Revenues Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-7.57%-1.35%-4.69%-6%+6.17%
Cost Of Revenues
aa.aaaa.aaaa.aaaa.aaaa.aa9,3518,9338,2847,9528,200
Gross Profit
aa.aaaa.aaaa.aaaa.aaaa.aa7,5367,7267,5946,9737,646
Gross Profit Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-9.16%+2.52%-1.71%-8.18%+9.65%
Gross Profit Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa44.63%46.38%47.83%46.72%48.25%
Other Operating Expenses, Total
aa.aaaa.aaaa.aaaa.aaaa.aa4,8204,6714,5154,3114,466
Other Operating Expenses, Total Growth
R&D Expenses
Selling General & Admin Expenses
Other Operating Expenses
aa.aaaa.aaaa.aaaa.aaaa.aa-9.89%-3.09%-3.34%-4.52%+3.6%
aa.aaaa.aaaa.aaaa.aaaa.aa1,010997967838953
aa.aaaa.aaaa.aaaa.aaaa.aa3,8063,6713,5283,4453,498
aa.aaaa.aaaa.aaaa.aaaa.aa43202815
Operating Income
aa.aaaa.aaaa.aaaa.aaaa.aa2,7163,0553,0792,6623,180
Operating Income Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-7.84%+12.48%+0.79%-13.54%+19.46%
EBIT Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa16.08%18.34%19.39%17.84%20.07%
Net Interest Expenses
aa.aaaa.aaaa.aaaa.aaaa.aa-781-797-891-920-961
Net Interest Expenses Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+11.35%-2.05%-11.79%-3.25%-4.46%
Interest Expense, Total
aa.aaaa.aaaa.aaaa.aaaa.aa-822-901-891-930-1,029
Interest And Investment Income
aa.aaaa.aaaa.aaaa.aaaa.aa41104-1068
Other Non Operating Expenses, Total
aa.aaaa.aaaa.aaaa.aaaa.aa-54101-67-25-94
EBT, Excl. Unusual Items
aa.aaaa.aaaa.aaaa.aaaa.aa1,8812,3592,1211,7172,125
Gain (Loss) On Sale Of Assets
aa.aaaa.aaaa.aaaa.aaaa.aa4919586428
Other Unusual Items, Total
aa.aaaa.aaaa.aaaa.aaaa.aa-3,010-1,897-1,289-2,732-1,964
EBT, Incl. Unusual Items
aa.aaaa.aaaa.aaaa.aaaa.aa-1,279-4,267667-3,142-622
EBT, Incl. Unusual Items Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+52.04%-233.62%+115.63%-571.06%+80.2%
EBT, Incl. Unusual Items Margin
aa.aaaa.aaaa.aaaa.aaaa.aa-7.57%-25.61%4.2%-21.05%-3.93%
Income Tax Expense
aa.aaaa.aaaa.aaaa.aaaa.aa-278-168211-643-7
Net Income to Company
aa.aaaa.aaaa.aaaa.aaaa.aa-1,001-4,099456-2,499-615
Minority Interest
aa.aaaa.aaaa.aaaa.aaaa.aa2109-395356
Net Income
aa.aaaa.aaaa.aaaa.aaaa.aa-999-3,990417-2,446-559
Net Income Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+53.53%-299.4%+110.45%-686.57%+77.15%
Net Income Margin %
aa.aaaa.aaaa.aaaa.aaaa.aa-5.92%-23.95%2.63%-16.39%-3.53%
Preferred Dividend and Other Adjustments
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Net Income to Common Excl. Extra Items
aa.aaaa.aaaa.aaaa.aaaa.aa-999-3,990417-2,446-559
Basic EPS - Continuing Operations
aa.aaaa.aaaa.aaaa.aaaa.aa-0.92-3.640.38-2.2-0.5
Basic EPS - Continuing Operations Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+61.03%-297.94%+110.38%-682.34%+77.33%
Diluted EPS - Continuing Operations
aa.aaaa.aaaa.aaaa.aaaa.aa-0.92-3.640.38-2.2-0.5
Diluted EPS - Continuing Operations Growth
aa.aaaa.aaaa.aaaa.aaaa.aa+61.04%-297.94%+110.38%-682.34%+77.31%
Basic Weighted Average Shares Outstanding
aa.aaaa.aaaa.aaaa.aaaa.aa1,0911,0951,1021,1101,119
Diluted Weighted Average Shares Outstanding
aa.aaaa.aaaa.aaaa.aaaa.aa1,0911,0951,1071,1101,119
Dividend Per Share
aa.aaaa.aaaa.aaaa.aaaa.aa-----
Dividend Per Share Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-----
EBITDA
aa.aaaa.aaaa.aaaa.aaaa.aa4,4384,6124,4093,9704,333
EBITDA Growth
aa.aaaa.aaaa.aaaa.aaaa.aa-7.33%+3.92%-4.4%-9.96%+9.14%
EBITDA Margin %
aa.aa